Symbicort is Gaining Share of Recently Treated COPD Patients at the Expense of Advair

Decision Resources Unveils New Online Platform for Its Treatment Algorithms Service

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that patient share of AstraZeneca’s Symbicort in recently treated chronic obstructive pulmonary disease (COPD) patients increased by nearly 20 percent over 2010. Over the same time period, patient share of competing long-acting beta2 agonist/inhaled corticosteroid (LABA/ICS) combination agent GlaxoSmithKline’s Advair grew only two percent, suggesting that Symbicort has been gaining use at the expense of Advair, the COPD market sales leader.

According to Treatment Algorithms in Chronic Obstructive Pulmonary Disease, historical analysis of U.S. patient-level claims data from newly diagnosed COPD patients found that Advair’s patient share did not notably change while Symbicort’s demonstrated a steady uptake over the study period. Symbicort’s approval for COPD in February 2009 marked the arrival of the first-in-class competitor for Advair.

“A small minority of migrations that progress from another therapy to Symbicort in the fourth quarter of 2010 were movements to Symbicort from Advair, suggesting that physicians are willing to use Symbicort in place of Advair rather than reserving it primarily for patients previously treated with Advair,” said Decision Resources Therapeutic Area Director Madhuri Borde, Ph.D. “Symbicort’s first-line patient share is still less than one-third that of Advair, but its uptake over our study period indicates that it is gaining a foothold in the COPD treatment algorithm.”

Enhanced Service and Platform Now Available

The analysis is part of Decision Resources’ enhanced Treatment Algorithms Insight series, which features a new online platform. Interactive, user-friendly and with more graphical data views, the new platform enables users to easily toggle between diseases and time cohorts, which ultimately allows for more in-depth analysis on each line of therapy. Treatment Algorithms analysis is now updated quarterly to provide ongoing trending of product utilization by line of therapy and new therapy initiations. Through examination of U.S. patient-level claims data, Decision Resources’ Treatment Algorithms Insight series provides exceptional insight into physicians’ prescribing trends, from diagnosis through multiple courses of treatment, for a specific disease.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.



CONTACT:

Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
or
Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Clinical Trials  Pharmaceutical  Other Health  Research  Science

MEDIA:

Logo
 Logo

Suggested Articles

With momentum building in Pfizer’s gene therapy programs, it has bought a building in North Carolina where it will consolidate clinical manufacturing.

Novo Nordisk had been hoping to show its Tresiba could top Sanofi’s Toujeo in a head-to-head showdown, but it didn't quite get there.

GlaxoSmithKline won an FDA panel recommendation for its over-the-counter nicotine spray—but the backing didn’t come easy.